M
Michel A. Duchosal
Researcher at University Hospital of Lausanne
Publications - 103
Citations - 13434
Michel A. Duchosal is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Transplantation & Nicotinamide phosphoribosyltransferase. The author has an hindex of 29, co-authored 93 publications receiving 11647 citations. Previous affiliations of Michel A. Duchosal include Scripps Research Institute & University of Lausanne.
Papers
More filters
Journal ArticleDOI
Diagnosis and treatment of follicular lymphoma: an update.
Mario Bargetzi,Reto Baumann,Sergio Cogliatti,Pierre-Yves Dietrich,Michel A. Duchosal,Jeroen S. Goede,Felicitas Hitz,Carolin Konermann,Andreas Lohri,Ulrich Mey,Urban Novak,Alexandros Papachristofilou,Frank Stenner,Christian Taverna,Thilo Zander,Christoph Renner +15 more
TL;DR: There remains an unmet need for patients who have early relapses, those who are not responsive to anti-CD20 treatment regimens and for those in whom minimal residual disease persists even after immunochemotherapy.
Journal ArticleDOI
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.
Anne-Julie Cloux,Dominique Aubry,Mathieu Heulot,Christian Widmann,Oussama ElMokh,Francesco Piacente,Michele Cea,Alessio Nencioni,Axel Bellotti,Karima Bouzourene,Maxime Pellegrin,Lucia Mazzolai,Michel A. Duchosal,Aimable Nahimana +13 more
TL;DR: It is shown that APO866 induces ROS/RNS productions, which mediate its anti-leukemia effect, and these results support testing new combinatorial strategies to enhance the antitumor activities of APo866.
Journal ArticleDOI
Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.
Caroline S. Breton,Dominique Aubry,Vanessa Ginet,Julien Puyal,Mathieu Heulot,Christian Widmann,Michel A. Duchosal,Aimable Nahimana +7 more
TL;DR: The data demonstrates that the combination of a non-lethal dose of BL and low dose of APO866 optimizes significantly cell death on various PC lines over both compounds given separately and open new and promising combination in PC therapy.
Journal ArticleDOI
The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody
Aimable Nahimana,Dominique Aubry,Caroline S. Breton,Somi Reddy Majjigapu,Bernard Sordat,Pierre Vogel,Michel A. Duchosal +6 more
TL;DR: In vivo, combined administration of APO866 with RTX in a laboratory model of human aggressive lymphoma significantly decreased tumor burden and prolonged survival over single-agent treatment and the combination of RTX andAPO866 optimizes B-cell lymphoma apoptosis and therapeutic efficacy over both compounds administered separately.
Journal ArticleDOI
Study of Early Elevated Gas6 Plasma Level as a Predictor of Mortality in a Prospective Cohort of Patients with Sepsis
Grégoire Stalder,Yok-Ai Que,Sara Calzavarini,Sara Calzavarini,Laurent Burnier,Christophe Kosinski,Pierluigi Ballabeni,Thierry Roger,Thierry Calandra,Michel A. Duchosal,Lucas Liaudet,Philippe Eggimann,Anne Angelillo-Scherrer,Anne Angelillo-Scherrer +13 more
TL;DR: It seems that Gas6 plasma level within 24 hours of ICU admission may predicts in-ICU mortality in patients with sepsis, and could contribute to the identification of patients who may benefit most from more aggressive management.